Undisclosed Preclinical Pipeline
Oncology (Solid Tumors)
PreclinicalActive
Key Facts
About OncoResponse
OncoResponse is a Seattle-based, privately-held biotech founded in 2015, focused on immuno-oncology. The company's core strategy involves mining the B-cell repertoires of Elite Cancer Responders—patients with exceptional, durable responses to immunotherapy—to discover fully human monoclonal antibodies against novel immunosuppressive targets, particularly in the myeloid cell compartment. Its preclinical pipeline aims to overcome resistance in the tumor microenvironment (TME) and expand the benefits of immunotherapy to more patients. OncoResponse advances its programs through internal R&D and strategic collaborations with pharmaceutical partners.
View full company profileTherapeutic Areas
Other Oncology (Solid Tumors) Drugs
| Drug | Company | Phase |
|---|---|---|
| OATD-02 | Molecure | Phase I |
| ANXV | Annexin Pharmaceuticals | Preclinical |
| Athebody® DARPins for Targeted Radioligands (with POINT Biopharma) | Athebio | Pre-clinical |
| AB821 | Asher Biotherapeutics | Preclinical |
| VEGF Kinoid | Neovacs | Preclinical |
| Undisclosed Platform Program | Da Zen Theranostics | Pre-clinical |
| Compound42 | Abbmira Therapeutics | Pre-clinical |
| Clinical Decision Support Service | Curematch | Commercial |
| CV6-168 | CV6 Therapeutics | Phase 1a |
| Chemophototherapy (CPT) | POP Biotechnologies | Pre-clinical |
| HRD Testing Solution | SeqOne Genomics | Commercial |
| Platform Validation & Partnership Development | SingleCell Biotechnology | Pre-clinical |